The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease

John E Lewis, Steven E. Atlas, Oscar L. Higuera, Andrea Fiallo, Ammar Rasul, Ashar Farooqi, Olga Kromo, Laura A. Lantigua, Eduard Tiozzo, Judi Woolger, Sharon Goldberg, Armando J Mendez, Allan E Rodriguez, Janet Konefal

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.

Original languageEnglish (US)
Article number1751583
JournalEvidence-based Complementary and Alternative Medicine
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Dietary Supplements
Polysaccharides
Biomarkers
Placebos
Neutrophils
Interleukin-18
Blood Cell Count
Non-alcoholic Fatty Liver Disease
Oryza
arabinoxylan
Transferases
Eosinophils
Alkaline Phosphatase
Monocytes
Intercellular Signaling Peptides and Proteins
Oxidative Stress
Blood Platelets
Lymphocytes
Cytokines
Lipids

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease. / Lewis, John E; Atlas, Steven E.; Higuera, Oscar L.; Fiallo, Andrea; Rasul, Ammar; Farooqi, Ashar; Kromo, Olga; Lantigua, Laura A.; Tiozzo, Eduard; Woolger, Judi; Goldberg, Sharon; Mendez, Armando J; Rodriguez, Allan E; Konefal, Janet.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2018, 1751583, 01.01.2018.

Research output: Contribution to journalArticle

Lewis, JE, Atlas, SE, Higuera, OL, Fiallo, A, Rasul, A, Farooqi, A, Kromo, O, Lantigua, LA, Tiozzo, E, Woolger, J, Goldberg, S, Mendez, AJ, Rodriguez, AE & Konefal, J 2018, 'The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease', Evidence-based Complementary and Alternative Medicine, vol. 2018, 1751583. https://doi.org/10.1155/2018/1751583
Lewis, John E ; Atlas, Steven E. ; Higuera, Oscar L. ; Fiallo, Andrea ; Rasul, Ammar ; Farooqi, Ashar ; Kromo, Olga ; Lantigua, Laura A. ; Tiozzo, Eduard ; Woolger, Judi ; Goldberg, Sharon ; Mendez, Armando J ; Rodriguez, Allan E ; Konefal, Janet. / The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease. In: Evidence-based Complementary and Alternative Medicine. 2018 ; Vol. 2018.
@article{e95a5056646444378096099176e70352,
title = "The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease",
abstract = "The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1{\%}; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9{\%}; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6{\%}; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156{\%}; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1{\%}; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.",
author = "Lewis, {John E} and Atlas, {Steven E.} and Higuera, {Oscar L.} and Andrea Fiallo and Ammar Rasul and Ashar Farooqi and Olga Kromo and Lantigua, {Laura A.} and Eduard Tiozzo and Judi Woolger and Sharon Goldberg and Mendez, {Armando J} and Rodriguez, {Allan E} and Janet Konefal",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/1751583",
language = "English (US)",
volume = "2018",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease

AU - Lewis, John E

AU - Atlas, Steven E.

AU - Higuera, Oscar L.

AU - Fiallo, Andrea

AU - Rasul, Ammar

AU - Farooqi, Ashar

AU - Kromo, Olga

AU - Lantigua, Laura A.

AU - Tiozzo, Eduard

AU - Woolger, Judi

AU - Goldberg, Sharon

AU - Mendez, Armando J

AU - Rodriguez, Allan E

AU - Konefal, Janet

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.

AB - The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=85048205472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048205472&partnerID=8YFLogxK

U2 - 10.1155/2018/1751583

DO - 10.1155/2018/1751583

M3 - Article

AN - SCOPUS:85048205472

VL - 2018

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 1751583

ER -